Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.47 Insider Own0.10% Shs Outstand156.54M Perf Week2.79%
Market Cap6.80B Forward P/E- EPS next Y-0.49 Insider Trans327.86% Shs Float153.94M Perf Month-23.79%
Income-225.20M PEG- EPS next Q-0.37 Inst Own97.57% Short Float6.17% Perf Quarter-15.75%
Sales393.10M P/S17.30 EPS this Y17.50% Inst Trans0.87% Short Ratio5.34 Perf Half Y2.54%
Book/sh4.24 P/B10.08 EPS next Y70.30% ROA-29.50% Target Price59.13 Perf Year45.44%
Cash/sh4.14 P/C10.33 EPS next 5Y25.00% ROE-33.50% 52W Range23.77 - 58.72 Perf YTD-0.12%
Dividend- P/FCF- EPS past 5Y-10.90% ROI-35.40% 52W High-27.23% Beta1.58
Dividend %- Quick Ratio8.40 Sales past 5Y390.00% Gross Margin94.80% 52W Low79.76% ATR2.01
Employees570 Current Ratio8.50 Sales Q/Q32.30% Oper. Margin-59.90% RSI (14)39.03 Volatility3.39% 3.80%
OptionableYes Debt/Eq0.00 EPS Q/Q29.30% Profit Margin-57.30% Rel Volume0.75 Prev Close43.63
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume1.78M Price42.73
Recom1.60 SMA20-9.45% SMA50-12.11% SMA200-5.47% Volume1,338,634 Change-2.06%
Jul-07-20Upgrade Stifel Hold → Buy $41 → $71
Apr-16-20Initiated Jefferies Buy $60
Mar-31-20Upgrade Goldman Neutral → Buy $45 → $72
Mar-06-20Initiated Citigroup Buy $69
Dec-16-19Initiated Guggenheim Buy $60
Oct-24-19Initiated Oppenheimer Perform $44
Oct-01-19Initiated RBC Capital Mkts Outperform $60
Sep-13-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19Upgrade Canaccord Genuity Hold → Buy $29 → $50
Jul-23-19Reiterated Needham Buy $40 → $34
Dec-10-18Initiated Canaccord Genuity Hold $23
Sep-21-18Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18Reiterated Stifel Hold $17 → $14
Aug-07-18Initiated Stifel Hold $17
Aug-06-18Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Aug-06-20 01:19PM  
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
Zacks
Aug-05-20 06:25PM  
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
Zacks
04:05PM  
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
Business Wire
Jul-31-20 08:00PM  
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)
Newsfile
Jul-30-20 03:37PM  
SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD)
Business Wire
Jul-29-20 12:33PM  
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks
09:00AM  
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
Business Wire
Jul-28-20 11:33AM  
ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?
Zacks
Jul-22-20 04:05PM  
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
Business Wire
12:32PM  
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks
Jul-21-20 04:24PM  
Acadia Pharma Dives On Unexpected Flop In Depression Treatment
Investor's Business Daily -19.36%
03:46AM  
Acadia Plunges 12% As Depressive Study Misses Goals; Analyst Says Buy
SmarterAnalyst
Jul-20-20 05:30PM  
U.S. FDA accepts Acadia's application for dementia drug
Reuters
04:03PM  
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
Business Wire
04:02PM  
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
Business Wire
Jul-12-20 08:54PM  
Did Hedge Funds Make The Right Call On ACADIA Pharmaceuticals Inc. (ACAD) ?
Insider Monkey
Jul-08-20 06:51AM  
Shareholders Are Thrilled That The ACADIA Pharmaceuticals (NASDAQ:ACAD) Share Price Increased 113%
Simply Wall St.
Jul-07-20 10:42AM  
Why Acadia Pharmaceuticals (ACAD) Stock is a Compelling Investment Case
Insider Monkey +6.17%
Jun-29-20 03:50PM  
Biotech Could Burst Higher, Says Signal
Schaeffer's Investment Research
Jun-17-20 07:36PM  
3 Strong Buy Healthcare Stocks That Should Remain Healthy
TipRanks
Jun-16-20 10:47AM  
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
Zacks
06:00AM  
Acadia Files Nuplazid Label Expansion; Analyst Sees Significant Potential
SmarterAnalyst
Jun-15-20 09:00AM  
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
Business Wire
Jun-08-20 03:37AM  
Hedge Funds Are Selling ACADIA Pharmaceuticals Inc. (ACAD)
Insider Monkey
Jun-06-20 11:31AM  
Why Is Acadia (ACAD) Down 7.6% Since Last Earnings Report?
Zacks
Jun-02-20 09:00AM  
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
Business Wire
07:27AM  
Is Acadia Pharmaceuticals a Buy?
Motley Fool
May-28-20 09:00AM  
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
Business Wire
May-27-20 12:15PM  
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
Zacks
May-26-20 09:00AM  
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
Business Wire
May-21-20 11:28PM  
Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents
09:00AM  
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
Business Wire
May-09-20 08:02AM  
Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) First-Quarter Report
Simply Wall St.
May-08-20 10:31PM  
Acadia Pharmaceuticals (ACAD) Q1 2020 Earnings Call Transcript
Motley Fool
10:55AM  
ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks
May-07-20 06:10PM  
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
Zacks
04:06PM  
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
Business Wire
04:05PM  
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
Business Wire
May-05-20 04:05PM  
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
Business Wire
Apr-30-20 12:34PM  
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
Apr-15-20 04:05PM  
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
Business Wire
Apr-13-20 09:43AM  
We're Not Worried About ACADIA Pharmaceuticals's (NASDAQ:ACAD) Cash Burn
Simply Wall St.
Mar-27-20 11:31AM  
Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report?
Zacks
Mar-24-20 04:23PM  
Biotech stocks have held up better than the broader market and these five are potential winners
MarketWatch +8.74%
Mar-22-20 05:04PM  
Largest Insider Trades of the Week
GuruFocus.com
Mar-20-20 02:11PM  
Hedge Funds Have Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD)
Insider Monkey
Mar-17-20 12:06AM  
Edited Transcript of ACAD earnings conference call or presentation 26-Feb-20 10:00pm GMT
Thomson Reuters StreetEvents +8.63%
Mar-03-20 05:50PM  
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
Business Wire
Feb-28-20 08:35PM  
Dont Expect Virgin Galactic Shares to Keep Rocketing Upward
Barrons.com +9.31%
01:54PM  
ACADIA Pharmaceuticals Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Simply Wall St.
Feb-27-20 11:13AM  
ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales
Zacks
Feb-26-20 05:35PM  
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates
Zacks
04:05PM  
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Business Wire
Feb-24-20 09:00AM  
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
Business Wire -6.38%
Feb-19-20 12:31PM  
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks
Feb-12-20 09:00AM  
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
Business Wire
Feb-05-20 06:13AM  
Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Simply Wall St.
Jan-29-20 05:00AM  
ACADIA- From Depression to Schizophrenia
MoneyShow
Jan-17-20 08:45AM  
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
Zacks
Jan-10-20 11:54AM  
How Did ACADIA Pharmaceuticals Inc. (ACAD) Perform In Comparison to Hedge Fund Favorites in 2019?
Insider Monkey
Jan-07-20 09:00AM  
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
Business Wire
Dec-23-19 02:47PM  
Investors flock to neuro drug makers after FDA approves new schizophrenia drug
MarketWatch
11:30AM  
Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?
Zacks
Dec-22-19 07:12AM  
Can You Imagine How Chuffed ACADIA Pharmaceuticals's (NASDAQ:ACAD) Shareholders Feel About Its 215% Share Price Gain?
Simply Wall St.
Dec-19-19 10:18AM  
Biotech Stock Outlook: M&A Activity Retains Growth Streak
Zacks
Dec-18-19 04:05PM  
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
Business Wire -5.81%
Dec-17-19 09:11AM  
5 Biotech Stocks That Have More Than Doubled This Year
Zacks
Dec-12-19 11:56AM  
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
Zacks
Dec-11-19 09:04AM  
5 Biotech Stocks Up More Than 100% This Year So Far
Zacks
Dec-06-19 07:39AM  
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Benzinga
05:00AM  
A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know
Barrons.com
Dec-05-19 11:01PM  
Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. (ACAD) Before The Q4 Rally
Insider Monkey +14.00%
04:08PM  
Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone
Investor's Business Daily
10:08AM  
Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data
Barrons.com
07:14AM  
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Benzinga
Dec-04-19 08:45PM  
Acadia Pharma's psychosis drug proven better than placebo in dementia patients
Reuters
08:45PM  
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimers Disease (CTAD) Meeting
Business Wire
Dec-02-19 02:57PM  
7 Exciting Biotech Stocks to Buy Now
InvestorPlace
Dec-01-19 09:30AM  
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Benzinga
07:27AM  
3 Monster Growth Stocks That Are Still in the Buy Zone
TipRanks
Nov-27-19 10:00AM  
What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?
Zacks
Nov-25-19 04:03PM  
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
Business Wire
08:58AM  
Top Ranked Momentum Stocks to Buy for November 25th
Zacks
Nov-21-19 09:56AM  
The Medicines Company Soars Amid Acquisition Whispers
Investopedia
Nov-18-19 10:17AM  
Medtronic (MDT) to Report Q2 Earnings: What's in Store?
Zacks
Nov-12-19 08:18AM  
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
Zacks
Nov-11-19 04:48PM  
IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity
Investor's Business Daily +6.17%
09:28AM  
4 Biotech Stocks That Could Keep Beating Wall Street
Zacks
09:00AM  
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimers Disease (CTAD) Meeting on December 4, 2019
Business Wire
Nov-07-19 05:13AM  
Have Insiders Been Selling ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares?
Simply Wall St.
Nov-06-19 10:00AM  
What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?
Zacks
09:00AM  
Acadia (ACAD) Upgraded to Buy: Here's Why
Zacks
Nov-04-19 05:40PM  
Edited Transcript of ACAD earnings conference call or presentation 30-Oct-19 8:30pm GMT
Thomson Reuters StreetEvents
09:00AM  
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
Business Wire
Oct-30-19 07:25PM  
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:15PM  
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
Business Wire
04:05PM  
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
Business Wire
Oct-29-19 08:46AM  
Cigna (CI) to Report Q3 Earnings: What's in the Offing?
Zacks
Oct-28-19 11:22AM  
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
Zacks
Oct-25-19 12:12PM  
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?
Zacks
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YANG MICHAEL J.EVP and CCOJul 07Option Exercise23.0027,250626,77032,454Jul 09 06:26 PM
YANG MICHAEL J.EVP and CCOJul 07Sale56.2527,2501,532,7865,204Jul 09 06:26 PM
Stankovic Srdjan R.PresidentJun 19Option Exercise18.1216,452298,11027,786Jun 19 06:55 PM
Stankovic Srdjan R.PresidentJun 19Sale50.1216,452824,51511,334Jun 19 06:55 PM
Stankovic Srdjan R.PresidentJun 18Option Exercise18.8165,8431,238,69777,177Jun 19 06:55 PM
Stankovic Srdjan R.PresidentJun 18Sale50.0165,8433,292,72911,334Jun 19 06:55 PM
DAVIS STEPHENCEOMay 14Option Exercise19.6588,5421,739,850100,351May 15 07:11 PM
DAVIS STEPHENCEOMay 14Sale45.6288,5424,039,10511,809May 15 07:11 PM
DAVIS STEPHENCEOMay 13Option Exercise19.65111,4582,190,150123,267May 15 07:11 PM
DAVIS STEPHENCEOMay 13Sale46.35111,4585,165,58711,809May 15 07:11 PM
Daly James MDirectorMay 11Option Exercise26.3926,250692,70026,250May 13 06:00 PM
Daly James MDirectorMay 11Sale51.1326,2501,342,1780May 13 06:00 PM
DAVIS STEPHENCEOApr 30Sale49.216,770333,15211,809May 01 06:00 PM
YANG MICHAEL J.EVP and CCOApr 30Sale49.211,50173,8645,204May 01 06:00 PM
KIM AUSTIN D.EVP & General CounselApr 30Sale49.221,07252,7642,441May 01 06:00 PM
Stankovic Srdjan R.PresidentApr 30Sale49.214,308211,99711,334May 01 06:00 PM
Ridloff ElenaEVP and CFOApr 30Sale49.221,05051,6812,195May 01 06:00 PM
Ridloff ElenaEVP and CFOApr 29Option Exercise25.1210,000251,20010,000May 01 06:00 PM
Ridloff ElenaEVP and CFOApr 29Sale50.7410,000507,3530May 01 06:00 PM
Stankovic Srdjan R.PresidentApr 23Option Exercise20.6718,949391,70424,976Apr 24 06:00 PM
Stankovic Srdjan R.PresidentApr 23Sale50.0718,949948,7296,027Apr 24 06:00 PM
Stankovic Srdjan R.PresidentApr 22Option Exercise19.7754,0191,067,95660,046Apr 22 06:30 PM
Stankovic Srdjan R.PresidentApr 22Sale50.0254,0192,701,9066,027Apr 22 06:30 PM
Stankovic Srdjan R.PresidentApr 20Option Exercise19.65100,0001,965,000106,027Apr 22 06:30 PM
Stankovic Srdjan R.PresidentApr 20Sale50.15100,0005,015,4506,027Apr 22 06:30 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy33.52135,8974,555,10138,433,977Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy32.84219,8007,218,90738,309,339Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy31.51694,30321,878,01738,107,749Mar 18 06:47 PM
Brege LauraDirectorJan 07Option Exercise1.7510,00017,50010,000Jan 08 06:01 PM
Brege LauraDirectorJan 07Sale42.1910,000421,9000Jan 08 06:01 PM
YANG MICHAEL J.EVP and CCODec 12Option Exercise31.09105,4793,279,377107,978Dec 13 05:35 PM
YANG MICHAEL J.EVP and CCODec 12Sale44.46105,4794,689,2632,499Dec 13 05:35 PM
KIM AUSTIN D.EVP & General CounselDec 11Option Exercise17.5817,500307,65018,009Dec 13 05:34 PM
KIM AUSTIN D.EVP & General CounselDec 11Sale45.0617,500788,576509Dec 13 05:34 PM
Ridloff ElenaEVP and CFODec 09Option Exercise15.8136,000569,16036,000Dec 11 06:29 PM
YANG MICHAEL J.EVP and CCODec 09Option Exercise35.8614,521520,72316,144Dec 11 06:30 PM
YANG MICHAEL J.EVP and CCODec 09Sale50.4614,521732,7921,623Dec 11 06:30 PM
Ridloff ElenaEVP and CFODec 09Sale49.6636,0001,787,8530Dec 11 06:29 PM
DAVIS STEPHENCEODec 05Option Exercise19.65150,0002,947,500152,954Dec 06 06:25 PM
DAVIS STEPHENCEODec 05Sale52.34150,0007,851,3002,954Dec 06 06:25 PM
Stankovic Srdjan R.PresidentNov 19Sale46.412,160100,2466,027Nov 21 05:37 PM
Miller Eric AlejandroController & PAOOct 15Sale39.651475,829270Oct 17 06:26 PM
YANG MICHAEL J.EVP and CCOOct 15Sale39.6587734,7731,623Oct 17 06:25 PM
Stankovic Srdjan R.PresidentOct 15Sale39.651,03140,8791,937Oct 17 06:24 PM
DAVIS STEPHENCEOOct 15Sale39.652,983118,2762,954Oct 17 06:23 PM
DAVIS STEPHENCEOOct 10Option Exercise19.65120,2082,362,087120,208Oct 11 05:39 PM
DAVIS STEPHENCEOOct 10Sale40.19120,2084,831,0390Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Option Exercise19.6529,792585,41329,792Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Sale40.0029,7921,191,7100Oct 11 05:39 PM
BAKER BROS. ADVISORS LPDirectorSep 20Buy40.001,562,50062,500,00037,470,965Sep 20 04:28 PM
Miller Eric AlejandroController & PAOSep 11Sale41.184,645191,2810Sep 11 07:19 PM
Daly James MDirectorSep 09Option Exercise17.5230,000525,60030,000Sep 11 07:18 PM
Miller Eric AlejandroController & PAOSep 09Option Exercise28.7128,467817,21833,112Sep 11 07:19 PM
Miller Eric AlejandroController & PAOSep 09Sale39.4928,4671,124,1624,645Sep 11 07:19 PM
Daly James MDirectorSep 09Sale37.8030,0001,133,8600Sep 11 07:18 PM
open in yahoo | open in reuters | open in google